{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:29Z","timestamp":1791475409885,"version":"4.3.4"},"reference-count":76,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eor.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>The aim of the study was to evaluate the efficacy and safety of teriparatide compared to other treatments for postmenopausal osteoporosis.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>A review of studies from 2000 to January 2023 analyzed randomized controlled trials on postmenopausal women treated with teriparatide (PTH 1\u201334), comparing it to placebo or other osteoporosis treatments. The analysis focused on bone mineral density (BMD), bone turnover markers, and clinical outcomes, employing Review Manager 5.4.1 and the RoB 2 tool for bias assessment.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>\n                          Our analysis of 23 randomized controlled trials (RCTs) found that PTH (134) treatment significantly increased lumbar spine BMD (mean difference (MD)\u2009=\u20090.02, 95% CI: 0.01\u20130.03) and femoral neck BMD (MD\u2009=\u20090.01, 95% CI: 0.00\u20130.01). However, there were no significant changes in total hip and radial bone BMD among the 3536 and 2046 participants, respectively. We also found that PTH (1\u201334) increased P1NP in a larger cohort (\n                          <jats:italic>n<\/jats:italic>\n                          \u2009=\u20091415) when compared to osteocalcin (\n                          <jats:italic>n<\/jats:italic>\n                          \u2009=\u2009206). Although the risk of adverse events increased (relative risk (RR)\u2009=\u20091.65, 95% CI: 1.32\u20132.07), the incidence of fractures decreased significantly (RR\u2009=\u20090.57, 95% CI: 0.45\u20130.072), with no significant difference observed in mortality rates between treatment and control groups.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Teriparatide improves lumbar spine and femoral neck BMD in postmenopausal women. Particularly notable is the novel finding regarding its effect on radius BMD, an area less explored in previous research. Despite an uptick in adverse events, the marked decrease in fracture incidence confirms its clinical utility for high-risk osteoporosis patients, highlighting the necessity for ongoing investigations into its full skeletal effects.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/eor-23-0205","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:36:11Z","timestamp":1725276971000},"page":"845-861","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":10,"title":["Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments \u2013 a systematic review and meta-analysis"],"prefix":"10.1530","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-7266","authenticated-orcid":true,"given":"Djandan Tadum","family":"Arthur Vithran","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anko Elijah","family":"Essien","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Rahmati","sequence":"additional","affiliation":[{"name":"Research Centre on Health Services and Quality of Life, Aix Marseille University, Marseille, France"},{"name":"Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran"},{"name":"Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Opoku","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Keon Yon","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea"},{"name":"Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo F","family":"L\u00f3pez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine and Public Health, Department of Public Health Sciences, School of Medicine, University of Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Koyanagi","sequence":"additional","affiliation":[{"name":"Research and Development Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[{"name":"Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Il Shin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, Honghui Hospital, Xi\u2019an Jiaotong University, Xi\u2019an, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Journal of Bone and Mineral Research","first-page":"1137","article-title":"The diagnosis of osteoporosis","volume":"9","author":"Kanis","year":"1994","unstructured":"Kanis JAMelton LJChristiansen CJohnston CC & Khaltaev N. The diagnosis of osteoporosis. Journal of Bone and Mineral Research199491137\u20131141. (https:\/\/doi.org\/10.1002\/jbmr.5650090802)"},{"key":"bib2","series-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","first-page":"1","volume":"843","year":"1994","unstructured":"Report of a WHO Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization Technical Report Series19948431\u201329."},{"key":"bib3","series-title":"Lancet","first-page":"364","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","unstructured":"Compston JEMcClung MR & Leslie WD. Osteoporosis. Lancet2019393364\u2013376. (https:\/\/doi.org\/10.1016\/S0140-6736(1832112-3)"},{"key":"bib4","series-title":"Osteoporosis International","first-page":"777","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","unstructured":"van Staa TPLeufkens HG & Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International200213777\u2013787. (https:\/\/doi.org\/10.1007\/s001980200108)"},{"key":"bib5","series-title":"Endocrinology and Metabolism Clinics of North America","first-page":"341","article-title":"Osteoporosis associated with excess glucocorticoids","volume":"34","author":"Shaker","year":"2005","unstructured":"Shaker JL & Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinology and Metabolism Clinics of North America200534341\u2013356. (https:\/\/doi.org\/10.1016\/j.ecl.2005.01.014)"},{"key":"bib6","series-title":"Lancet","first-page":"1116","article-title":"More DATA to guide sequential osteoporosis therapy","volume":"386","author":"Hofbauer","year":"2015","unstructured":"Hofbauer LC & Rachner TD. More DATA to guide sequential osteoporosis therapy. Lancet20153861116\u20131118. (https:\/\/doi.org\/10.1016\/S0140-6736(1561175-8)"},{"key":"bib7","series-title":"Lancet","first-page":"1276","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","unstructured":"Rachner TDKhosla S & Hofbauer LC. Osteoporosis: now and the future. Lancet20113771276\u20131287. (https:\/\/doi.org\/10.1016\/S0140-6736(1062349-5)"},{"key":"bib8","series-title":"Archives of Internal Medicine","first-page":"2026","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","unstructured":"Chrischilles EAButler CDDavis CS & Wallace RB. A model of lifetime osteoporosis impact. Archives of Internal Medicine19911512026\u20132032. (https:\/\/doi.org\/10.1001\/archinte.1991.00400100100017)"},{"key":"bib9","series-title":"New England Journal of Medicine","first-page":"412","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","unstructured":"McClung MRGrauer ABoonen SBolognese MABrown JPDiez-Perez ALangdahl BLReginster JYZanchetta JRWasserman SM, et al.Romosozumab in postmenopausal women with low bone mineral density. New England Journal of Medicine2014370412\u2013420. (https:\/\/doi.org\/10.1056\/NEJMoa1305224)"},{"key":"bib10","series-title":"Osteoporosis International","first-page":"675","article-title":"The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic\/pharmacodynamic study","volume":"30","author":"Tak\u00e1cs","year":"2019","unstructured":"Tak\u00e1cs IJ\u00f3kai EKov\u00e1ts DE & Aradi I. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic\/pharmacodynamic study. Osteoporosis International201930675\u2013683. (https:\/\/doi.org\/10.1007\/s00198-018-4741-0)"},{"key":"bib11","series-title":"Drugs and Aging","first-page":"845","article-title":"Romosozumab: a review in postmenopausal osteoporosis","volume":"37","author":"Paik","year":"2020","unstructured":"Paik J & Scott LJ. Romosozumab: a review in postmenopausal osteoporosis. Drugs and Aging202037845\u2013855. (https:\/\/doi.org\/10.1007\/s40266-020-00793-8)"},{"key":"bib12","series-title":"Bone","first-page":"1434","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","unstructured":"Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone2007401434\u20131446. (https:\/\/doi.org\/10.1016\/j.bone.2007.03.017)"},{"key":"bib13","series-title":"Bone","first-page":"237","article-title":"Bone tissue and its mineralization in aged estrogen-depleted rats after longterm intermittent treatment with parathyroid hormone (PTH)analog SDZ PTS 893 or human PTH(1\u201334)","volume":"28","author":"Kneissel","year":"2001","unstructured":"Kneissel MBoyde A & Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after longterm intermittent treatment with parathyroid hormone (PTH)analog SDZ PTS 893 or human PTH(1\u201334). Bone200128237\u2013250. (https:\/\/doi.org\/10.1016\/s8756-3282(0000448-8)"},{"key":"bib14","series-title":"Nature Reviews. Endocrinology","first-page":"647","article-title":"Parathyroid hormone analogues in the treatment of osteoporosis","volume":"7","author":"Kraenzlinand","year":"2011","unstructured":"Kraenzlinand ME & Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nature Reviews. Endocrinology20117647\u2013656. (https:\/\/doi.org\/10.1038\/nrendo.2011.108)"},{"key":"bib15","series-title":"Journal of Bone and Mineral Research","first-page":"841","article-title":"Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide","volume":"22","author":"Chen","year":"2007","unstructured":"Chen PJerome CPBurr DBTurner CHMa YLRana A & Sato M. Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide. Journal of Bone and Mineral Research200722841\u2013848. (https:\/\/doi.org\/10.1359\/jbmr.070310)"},{"key":"bib16","series-title":"Journal of Bone and Mineral Research","first-page":"1932","article-title":"Recombinant human parathyroid hormone(1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","unstructured":"Jiang YZhao JJMitlak BHWang OGenant HK & Eriksen EF. \u201cRecombinant human parathyroid hormone(1\u201334) [teriparatide] improves both cortical and cancellous bone structure.\u201d Journal of Bone and Mineral Research2003181932\u20131941. (https:\/\/doi.org\/10.1359\/jbmr.2003.18.11.1932)"},{"key":"bib17","series-title":"Journal of Bone and Mineral Research","first-page":"1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","unstructured":"Dempster DWCosman FKurland ESZhou HNieves JWoelfert LShane EPlaveti\u0107 KM\u00fcller RBilezikian J, et al.Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Journal of Bone and Mineral Research2001161846\u20131853. (https:\/\/doi.org\/10.1359\/jbmr.2001.16.10.1846)"},{"key":"bib18","series-title":"Bone","first-page":"1447","article-title":"Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure","volume":"40","author":"Compston","year":"2007","unstructured":"Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone2007401447\u20131452. (https:\/\/doi.org\/10.1016\/j.bone.2006.09.008)"},{"key":"bib19","series-title":"Bone","first-page":"139","article-title":"Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment","volume":"59","author":"Ma","year":"2014","unstructured":"Ma YLZeng QQChiang AYBurr DLi JDobnig HFahrleitner-Pammer AMichalsk\u00e1 DMarin FPavo I, et al.Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone201459139\u2013147. (https:\/\/doi.org\/10.1016\/j.bone.2013.11.011)"},{"key":"bib20","series-title":"New England Journal of Medicine","first-page":"1434","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","unstructured":"Neer RMArnaud CDZanchetta JRPrince RGaich GAReginster JYHodsman ABEriksen EFIsh-Shalom SGenant HK, et al.Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine20013441434\u20131441. (https:\/\/doi.org\/10.1056\/NEJM200105103441904)"},{"key":"bib21","series-title":"Osteoporosis International","first-page":"510","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","unstructured":"Kaufman JMOrwoll EGoemaere SSan Martin JHossain ADalsky GP: Lindsay RMitlak BH. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis International. 200516510\u2013516."},{"key":"bib22","series-title":"Archives of Internal Medicine","first-page":"2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","unstructured":"Lindsay RScheele WHNeer RPohl GAdami SMautalen CReginster JYStepan JJMyers SL & Mitlak BH. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Archives of Internal Medicine20041642024\u20132030. (https:\/\/doi.org\/10.1001\/archinte.164.18.2024)"},{"key":"bib23","series-title":"Clinics in Geriatric Medicine","first-page":"415","article-title":"The anabolic effects of parathyroid hormone therapy","volume":"19","author":"Rubin","year":"2003","unstructured":"Rubin MR & Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clinics in Geriatric Medicine200319415\u2013432. (https:\/\/doi.org\/10.1016\/s0749-0690(0200074-5)"},{"key":"bib24","series-title":"Osteoporosis International","first-page":"1163","article-title":"The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT","volume":"25","author":"Ito","year":"2014","unstructured":"Ito MOishi RFukunagaetal MSone TSugimoto TShiraki MNishizawa Y & Nakamura T. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporosis International2014251163\u20131172. (https:\/\/doi.org\/10.1007\/s00198-013-2596-y)"},{"key":"bib25","series-title":"Bone","first-page":"678","article-title":"Human parathyroid hormone (1\u201334) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femoral","volume":"36","author":"Komatsubara","year":"2005","unstructured":"Komatsubara SMori SMashibaetal TNonaka KSeki AAkiyama TMiyamoto KCao YManabe T & Norimatsu H. Human parathyroid hormone (1\u201334) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femoral. Bone200536678\u2013687. (https:\/\/doi.org\/10.1016\/j.bone.2005.02.002)"},{"key":"bib26","series-title":"Bone","first-page":"480","article-title":"Effect of human parathyroid hormone hPTH (1\u201334) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats","volume":"47","author":"Komrakova","year":"2010","unstructured":"Komrakova MStuermer EKWerner CWicke MKolios LSehmisch STezval MDaub FMartens TWitzenhausen P, et al.Effect of human parathyroid hormone hPTH (1\u201334) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone201047480\u2013492. (https:\/\/doi.org\/10.1016\/j.bone.2010.05.013)"},{"key":"bib27","series-title":"Journal of Orthopaedic Research","first-page":"1474","article-title":"Role of parathyroid hormone in the mechanosensitivity of fracture healing","volume":"25","author":"Gardner","year":"2007","unstructured":"Gardner MJvan der Meulen MCHCarson JZelken JRicciardi BFWright TMLane JM & Bostrom MP. Role of parathyroid hormone in the mechanosensitivity of fracture healing. Journal of Orthopaedic Research2007-11-01 251474\u20131480. (https:\/\/doi.org\/10.1002\/jor.20427)"},{"key":"bib28","series-title":"Osteoporosis International","first-page":"1463","article-title":"The effects of combined human parathyroid hormone (1\u201334) and zoledronic acid treatment on fracture healing in osteoporotic rats","volume":"23","author":"Li","year":"2012","unstructured":"Li YFZhou CCLi JHLuo EZhu SSFeng G & Hu J. The effects of combined human parathyroid hormone (1\u201334) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporosis International2012231463\u20131474. (https:\/\/doi.org\/10.1007\/s00198-011-1751-6)"},{"key":"bib29","series-title":"BioMed Research International","first-page":"568390","article-title":"Effect of teriparatide on unstable pertrochanteric fractures","volume":"2015","author":"Huang","year":"2015","unstructured":"Huang T-WYang T-YHuang K-CPeng K-TLee MS & Hsu RW-W. Effect of teriparatide on unstable pertrochanteric fractures. BioMed Research International20152015568390. (https:\/\/doi.org\/10.1155\/2015\/568390)"},{"key":"bib30","series-title":"Journal of Bone and Mineral Research","first-page":"1027","article-title":"Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates","volume":"32","author":"Watts","year":"2017","unstructured":"Watts NBAggers DMcCarthy EFSavage TMartinez SPatterson RCarrithers E & Miller PD. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. Journal of Bone and Mineral Research2017321027\u20131033. (https:\/\/doi.org\/10.1002\/jbmr.3081)"},{"key":"bib31","series-title":"Journal of Bone Metabolism","first-page":"183","article-title":"Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review","volume":"22","year":"2015","unstructured":"GI Im & Lee SH.Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review. Journal of Bone Metabolism201522183\u2013189. (https:\/\/doi.org\/10.11005\/jbm.2015.22.4.183)"},{"key":"bib32","series-title":"Injury","first-page":"1425","article-title":"Enhancement of hip fracture healing in the elderly: evidence deriving from a pilot randomized trial","volume":"46","author":"Kanakaris","year":"2015","unstructured":"Kanakaris NKWest RM & Giannoudis PV. Enhancement of hip fracture healing in the elderly: evidence deriving from a pilot randomized trial. Injury2015461425\u20131428. (https:\/\/doi.org\/10.1016\/j.injury.2015.06.033)"},{"key":"bib33","series-title":"Acta Orthopaedica","first-page":"259","article-title":"No effect of teriparatide on migration in total knee replacement","volume":"88","author":"Ledin","year":"2017","unstructured":"Ledin HGood LJohansson T & Aspenberg P. No effect of teriparatide on migration in total knee replacement. Acta Orthopaedica201788259\u2013262. (https:\/\/doi.org\/10.1080\/17453674.2017.1300745)"},{"key":"bib34","series-title":"Calcified Tissue International","first-page":"343","article-title":"Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper","volume":"90","author":"Goldhahn","year":"2012","unstructured":"Goldhahn JF\u00e9ron JMKanis JPapapoulos SReginster JYRizzoli RDere WMitlak BTsouderos Y & Boonen S. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcified Tissue International201290343\u2013353. (https:\/\/doi.org\/10.1007\/s00223-012-9587-4)"},{"key":"bib35","series-title":"Bone","first-page":"39","article-title":"The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review","volume":"99","author":"Metcalf","year":"2017","unstructured":"Metcalf LMAspray TJ & McCloskey EV. The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review. Bone20179939\u201346. (https:\/\/doi.org\/10.1016\/j.bone.2017.03.007)"},{"key":"bib36","series-title":"Osteoporosis International","first-page":"811","article-title":"The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture","volume":"24","author":"Borgstr\u00f6m","year":"2013","unstructured":"Borgstr\u00f6m FLekander IIverg\u00e5rd MStr\u00f6m OSvedbom AAlekna VBianchi MLClark PCuriel MDDimai HP, et al.The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporosis International201324811\u2013823. (https:\/\/doi.org\/10.1007\/s00198-012-2240-2)"},{"key":"bib37","series-title":"Osteoporosis International","first-page":"2623","article-title":"The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality","volume":"26","author":"Marques","year":"2015","unstructured":"Marques ALourenco \u00d3da Silva JA & Portuguese Working Group for the Study of the Burden of Hip Fractures in Portugal. The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. Osteoporosis International2015262623\u20132630. (https:\/\/doi.org\/10.1007\/s00198-015-3171-5)"},{"key":"bib38","series-title":"Journal of Bone and Mineral Research","first-page":"581","article-title":"Trends in fracture incidence: a population-based study over 20 years","volume":"29","author":"Amin","year":"2014","unstructured":"Amin SAchenbach SJAtkinson EJKhosla S & Melton LJIII. Trends in fracture incidence: a population-based study over 20 years. Journal of Bone and Mineral Research201429581\u2013589. (https:\/\/doi.org\/10.1002\/jbmr.2072)"},{"key":"bib39","series-title":"Nature Reviews. Endocrinology","first-page":"593","article-title":"Osteocytic signalling pathways as therapeutic targets for bone fragility","volume":"12","author":"Plotkin","year":"2016","unstructured":"Plotkin LI & Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nature Reviews. Endocrinology201612593\u2013605. (https:\/\/doi.org\/10.1038\/nrendo.2016.71)"},{"key":"bib40","series-title":"Journal of Pineal Research","first-page":"e12548","article-title":"Melatonin: another avenue for treating osteoporosis?","volume":"66","author":"Li","year":"2019","unstructured":"Li TJiang SLu CYang WYang ZHu WXin Z & Yang Y. Melatonin: another avenue for treating osteoporosis?Journal of Pineal Research201966e12548. (https:\/\/doi.org\/10.1111\/jpi.12548)"},{"key":"bib41","series-title":"Endocrine Reviews","first-page":"240","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling","year":"2022","unstructured":"Ebeling PRNguyen HHAleksova JVincent AJWong P & Milat F. Secondary osteoporosis. Endocrine Reviews202243240\u2013313. (https:\/\/doi.org\/10.1210\/endrev\/bnab028)"},{"key":"bib42","series-title":"Regulatory Toxicology and Pharmacology","first-page":"356","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH (1\u201334)","volume":"86","author":"Jolette","year":"2017","unstructured":"Jolette JAttalla BVarela ALong GGMellal NTrimm SSmith SYOminsky MS & Hattersley G. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH (1\u201334). Regulatory Toxicology and Pharmacology201786356\u2013365. (https:\/\/doi.org\/10.1016\/j.yrtph.2017.04.001)"},{"key":"bib43","series-title":"Frontiers in Pharmacology","first-page":"265","article-title":"Rethinking the appraisal and approval of drugs for fracture prevention","volume":"8","author":"Erviti","year":"2017","unstructured":"Erviti JGorricho JSaiz LCPerry T & Wright JM. Rethinking the appraisal and approval of drugs for fracture prevention. Frontiers in Pharmacology20178265. (https:\/\/doi.org\/10.3389\/fphar.2017.00265)"},{"key":"bib44","series-title":"Journal of Bone and Mineral Research","first-page":"1407","article-title":"Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","unstructured":"Cosman FCrittenden DBFerrari SLewiecki EMJaller-Raad JZerbini CMilmont CEMeisner PDLibanati C & Grauer A. Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. Journal of Bone and Mineral Research2018331407\u20131416. (https:\/\/doi.org\/10.1002\/jbmr.3439)"},{"key":"bib45","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3183","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","unstructured":"Lewiecki EMBlicharski TGoemaere SLippuner KMeisner PDMiller PDMiyauchi AMaddox JChen L & Horlait S. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. Journal of Clinical Endocrinology and Metabolism20181033183\u20133193. (https:\/\/doi.org\/10.1210\/jc.2017-02163)"},{"key":"bib46","series-title":"New England Journal of Medicine","first-page":"1417","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","unstructured":"Saag KGPetersen JBrandi MLKaraplis ACLorentzon MThomas TMaddox JFan MMeisner PD & Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine20173771417\u20131427. (https:\/\/doi.org\/10.1056\/NEJMoa1708322)"},{"key":"bib47","series-title":"New England Journal of Medicine","first-page":"1532","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","unstructured":"Cosman FCrittenden DBAdachi JDBinkley NCzerwinski EFerrari SHofbauer LCLau ELewiecki EMMiyauchi A, et al.Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine20163751532\u20131543. (https:\/\/doi.org\/10.1056\/NEJMoa1607948)"},{"key":"bib48","series-title":"Journal of Bone and Mineral Research","first-page":"19","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","unstructured":"Padhi DJang GStouch BFang L & Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Journal of Bone and Mineral Research20112619\u201326. (https:\/\/doi.org\/10.1002\/jbmr.173)"},{"key":"bib49","series-title":"BMJ","first-page":"m2632","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist","volume":"370","author":"Salameh","year":"2020","unstructured":"Salameh JPBossuyt PMMcGrath TAThombs BDHyde CJMacaskill PDeeks JJLeeflang MKorevaar DAWhiting P, et al.Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ2020370m2632. (https:\/\/doi.org\/10.1136\/bmj.m2632)"},{"key":"bib50","series-title":"International Journal of Clinical Practice","first-page":"919","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial","volume":"62","author":"Anastasilakis","year":"2008","unstructured":"Anastasilakis ADGoulis DGPolyzos SAGerou SKoukoulis GNEfstathiadou ZKita M & Avramidis A & Avramidis A. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. International Journal of Clinical Practice200862919\u2013924. (https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01768.x)"},{"key":"bib51","series-title":"Lancet","first-page":"230","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomized controlled trial","volume":"391","author":"Kendler","year":"2018","unstructured":"Kendler DLMarin FZerbini CAFRusso LAGreenspan SLZikan VBagur AMalouf-Sierra JLakatos PFahrleitner-Pammer A, et al.Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet2018391230\u2013240. (https:\/\/doi.org\/10.1016\/S0140-6736(1732137-2)"},{"key":"bib52","series-title":"Journal of Bone and Mineral Research","first-page":"503","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1\u201334)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","unstructured":"Cosman FEriksen EFRecknor CMiller PDGua\u00f1abens NKasperk CPapanastasiou PReadie ARao HGasser JA, et al.Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1\u201334)] in postmenopausal osteoporosis. Journal of Bone and Mineral Research201126503\u2013511. (https:\/\/doi.org\/10.1002\/jbmr.238)"},{"key":"bib53","series-title":"Chinese Journal of Osteoporosis","first-page":"1276","article-title":"Comparative study of the efficacy of parathyroid hormone (1\u201334), strontium ranelate and zoledronic acid in postmenopausal osteoporosis","volume":"23","author":"Yingchun","year":"2017","unstructured":"Yingchun W & Hui S. Comparative study of the efficacy of parathyroid hormone (1\u201334), strontium ranelate and zoledronic acid in postmenopausal osteoporosis. Chinese Journal of Osteoporosis2017231276\u20131279."},{"key":"bib54","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4528","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","unstructured":"Body JJGaich GAScheele WHKulkarni PMMiller PDPeretz ADore RKCorrea-Rotter RPapaioannou ACumming DC, et al.A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism2002874528\u20134535. (https:\/\/doi.org\/10.1210\/jc.2002-020334)"},{"key":"bib55","series-title":"Medicine","first-page":"e13341","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis","volume":"97","author":"Deng","year":"2018","unstructured":"Deng JFeng ZLi YPan TLi Q & Zhao C. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. Medicine201897e13341. (https:\/\/doi.org\/10.1097\/MD.0000000000013341)"},{"key":"bib56","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1838","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","unstructured":"Finkelstein JSWyland JJLee H & Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism2010951838\u20131845. (https:\/\/doi.org\/10.1210\/jc.2009-1703)"},{"key":"bib57","series-title":"Archives of Internal Medicine","first-page":"1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","unstructured":"McClung MRSan Martin JMiller PDCivitelli RBandeira FOmizo MDonley DWDalsky GP & Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Archives of Internal Medicine, 20051651762\u20131768."},{"key":"bib58","series-title":"Journal of Bone and Mineral Research","first-page":"149","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","unstructured":"Keaveny TMDonley DWHoffmann PFMitlak BHGlass EV & San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. Journal of Bone and Mineral Research200722149\u2013157. (https:\/\/doi.org\/10.1359\/jbmr.061011)"},{"key":"bib59","series-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research","first-page":"259","article-title":"Effects of intermittent parathyroid hormone 1\u201334 administration on circulating mesenchymal stem cells in postmenopausal osteoporotic women","volume":"25","author":"Tang","year":"2019","unstructured":"Tang YXia HKang LSun QSu ZHao C & Xue Y. Effects of intermittent parathyroid hormone 1\u201334 administration on circulating mesenchymal stem cells in postmenopausal osteoporotic women. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research201925259\u2013268. (https:\/\/doi.org\/10.12659\/MSM.913752)"},{"key":"bib60","series-title":"Bone","first-page":"116416","article-title":"Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study","volume":"160","author":"Chiba","year":"2022","unstructured":"Chiba KOkazaki NKurogi AWatanabe TMori ASuzuki NAdachi KEra MYokota KInoue T, et al.Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study. Bone2022160116416. (https:\/\/doi.org\/10.1016\/j.bone.2022.116416)"},{"key":"bib61","series-title":"Journal of Clinical Medicine","first-page":"3043","article-title":"Efficacy and safety of postmenopausal osteoporosis treatments: a systematic review and network meta-analysis of randomized controlled trials","volume":"10","author":"Lin","year":"2021","unstructured":"Lin SYHung MCChang SFTsuang FYChang JZC & Sun JS. Efficacy and safety of postmenopausal osteoporosis treatments: a systematic review and network meta-analysis of randomized controlled trials. Journal of Clinical Medicine2021103043. (https:\/\/doi.org\/10.3390\/jcm10143043)"},{"key":"bib62","series-title":"Chinese Medical Journal","first-page":"457","article-title":"Comparison of parathyroid hormone (1\u201334) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China","volume":"126","author":"Li","year":"2013","unstructured":"Li YXuan MWang BYang JZhang HZhang XZGuo XHL\u00fc XFXue QYYang GY, et al.Comparison of parathyroid hormone (1\u201334) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chinese Medical Journal2013126457\u2013463. (https:\/\/doi.org\/10.3760\/cma.j.issn.0366-6999.20121626)"},{"key":"bib63","series-title":"Chinese Medical Journal","first-page":"2933","article-title":"A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1\u201334) with elcatonin in postmenopausal women with osteoporosis in China","volume":"122","author":"Zhang","year":"2009","unstructured":"Zhang XZWang BYang JXuan MSong LGLi HGuo XHL\u00fc XFXue QYYang GY, et al.A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1\u201334) with elcatonin in postmenopausal women with osteoporosis in China. Chinese Medical Journal20091222933\u20132938."},{"key":"bib64","series-title":"Asian Pacific Journal of Tropical Medicine","first-page":"79","article-title":"Comparison between recombinant human parathyroid hormone (1\u201334) and elcatonin in treatment of primary osteoporosis","volume":"8","author":"Yang","year":"2015","unstructured":"Yang YZhang XJZhu XJZhang LBao MJXian YWu JCLiu LM & Li PQ. Comparison between recombinant human parathyroid hormone (1\u201334) and elcatonin in treatment of primary osteoporosis. Asian Pacific Journal of Tropical Medicine2015879\u201384. (https:\/\/doi.org\/10.1016\/S1995-7645(1460192-9)"},{"key":"bib65","series-title":"Osteoporosis International","first-page":"1524","article-title":"Teriparatide\u2019s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis","volume":"17","author":"Gonnelli","year":"2006","unstructured":"Gonnelli SMartini GCaffarelli CSalvadori SCadirni AMontagnani A & Nuti R. Teriparatide\u2019s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporosis International2006171524\u20131531. (https:\/\/doi.org\/10.1007\/s00198-006-0157-3)"},{"key":"bib66","series-title":"Lancet","first-page":"50","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","unstructured":"Tsai JNUihlein AVLee HKumbhani RSiwila-Sackman EMcKay EABurnett-Bowie SAMNeer RM & Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet201338250\u201356. (https:\/\/doi.org\/10.1016\/S0140-6736(1360856-9)."},{"key":"bib67","series-title":"Lancet","first-page":"1147","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","unstructured":"Leder BZTsai JNUihlein AVWallace PMLee HNeer RM & Burnett-Bowie SAM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the data-switch study): extension of a randomised controlled trial. Lancet20153861147\u20131155. (https:\/\/doi.org\/10.1016\/S0140-6736(1561120-5)"},{"key":"bib68","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"697","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","unstructured":"Leder BZO'Dea LSLZanchetta JRKumar PBanks KMcKay KLyttle CR & Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism2015100697\u2013706. (https:\/\/doi.org\/10.1210\/jc.2014-3718)"},{"key":"bib69","series-title":"Journal of Bone and Mineral Research","first-page":"181","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone Mass.","volume":"32","author":"Genant","year":"2017","unstructured":"Genant HKEngelke KBolognese MAMautalen CBrown JPRecknor CGoemaere SFuerst TYang YCGrauer A, et al.Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone Mass.Journal of Bone and Mineral Research201732181\u2013187. (https:\/\/doi.org\/10.1002\/jbmr.2932)"},{"key":"bib70","series-title":"Journal of Bone and Mineral Research","first-page":"1956","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone Mass.","volume":"32","author":"Keaveny","year":"2017","unstructured":"Keaveny TMCrittenden DBBolognese MAGenant HKEngelke KOliveri BBrown JPLangdahl BLYan CGrauer A, et al.Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone Mass.Journal of Bone and Mineral Research2017321956\u20131962. (https:\/\/doi.org\/10.1002\/jbmr.3176)"},{"key":"bib71","series-title":"Lancet","first-page":"1585","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","unstructured":"Langdahl BLLibanati CCrittenden DBBolognese MABrown JPDaizadeh NSDokoupilova EEngelke KFinkelstein JSGenant HK, et al.Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet20173901585\u20131594. (https:\/\/doi.org\/10.1016\/S0140-6736(1731613-6)"},{"key":"bib72","series-title":"International Journal of Surgery","first-page":"1","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","unstructured":"Yuan FPeng WYang C & Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. International Journal of Surgery2019661\u201311. (https:\/\/doi.org\/10.1016\/j.ijsu.2019.03.004)"},{"key":"bib73","series-title":"Climacteric","first-page":"189","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","unstructured":"Liu YCao YZhang SZhang WZhang BTang QLi Z & Wu J. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric201821189\u2013195. (https:\/\/doi.org\/10.1080\/13697137.2018.1433655)"},{"key":"bib74","series-title":"Frontiers in Pharmacology","first-page":"888208","article-title":"Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Sun","year":"2022","unstructured":"Sun YLi YLi JXie XGu FSui ZZhang K & Yu T. Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis. Frontiers in Pharmacology202213888208. (https:\/\/doi.org\/10.3389\/fphar.2022.888208)"},{"key":"bib75","series-title":"Bone","first-page":"115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","unstructured":"Simpson ELMartyn-St James MHamilton JWong RGittoes NSelby P & Davis S. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone2020130115081. (https:\/\/doi.org\/10.1016\/j.bone.2019.115081)"},{"key":"bib76","series-title":"Journal of Orthopaedic Surgery and Research","first-page":"116","article-title":"Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis","volume":"18","author":"Hong","year":"2023","unstructured":"Hong PLiu RRai SLiu JZhou YZheng Y & Li J. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. Journal of Orthopaedic Surgery and Research202318116. (https:\/\/doi.org\/10.1186\/s13018-023-03595-x)"}],"container-title":["EFORT Open Reviews"],"original-title":[],"link":[{"URL":"https:\/\/eor.bioscientifica.com\/view\/journals\/eor\/9\/9\/EOR-23-0205.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/9\/9\/EOR-23-0205.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/9\/9\/EOR-23-0205.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:19Z","timestamp":1784555479000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eor\/article\/9\/9\/845-861\/2675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":76,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1530\/eor-23-0205","relation":{},"ISSN":["2058-5241"],"issn-type":[{"value":"2058-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}